Indeed, by using a loss-of-function approach, we confirmed that activation of the EGFR-IL-6 pathway and enrichment of paclitaxel-resistant CSCs depended on MUC1 expression in cervical cancer (Supplementary Fig. S3). This evidence concerns the gene MUC1 and cervical cancer.